Pathogenes Inc.
PO Box 970, Fairfield, Fl. 32634
15471 NW 112th Ave, Reddick, Fl. 32686
ph: 352-591-3221
fax: 352-591-4318
sellison
We are making progress with apicomplexan parasite diseases. We present recently published articles and new data as they are made public. We encourage you to take part in our ongoing research. Can't find what you are looking for? Try the archive page. Read about our newest progress on our BLOG, updated recently. Sort our blog by catagory to see all the posts on a single issue. Did you miss the Webinar? It's not too late... we will share the following WebEx recording with you. Click the link below:
A Novel Strategy for Treatment and Protection against EPM
12-29-2011
You can send a check with your test sample or click the PayPal button and pay for your Peptide ELISA on the services tab. You may also send in your credit card number and expiration date with your submission form and Intuit will take the payment for us.
December 2011
Our meeting to outline the steps to bring Oroquin-10 to market under a conditional license went well. If you are a veterinarian with a case of EPM please indicate your willingness to participate in our Phase II trial on the Peptide ELISA submission form. Or call us with questions, we will be happy to explain the protocol to you.
August 2011
We are getting positive feedback from veterinarians and horse owners that have used Oroquin-10 to assist in diagnosis and treatment of EPM. The first 60 days of the trial are discussed on our parasite research BLOG page. Success is a horse with marked improvment clinically and a reduction in antibody titer. The trial horses show 94% success with treatment using Oroquin-10. The field trial allows a veterinarian that determines there is a presumptive diagnosis of EPM based on clinical neurological exam and antibody testing to initiate thereapy for their patient. The therapy can support a diagnosis of EPM if there is a positive response to treatment. We colate the data for our field trial based on the veterinarians observations and our in house testing.
Clinical Field Trial using Oroquin-10
Cross-over Field Trial for chronic cases of EPM
Double blind, placebo controlled experimental infection trial
Licensing a drug through FDA takes from 5-10 years from project inception to full license. A similar period of time is needed for USDA licensing of diagnostic products and vaccines. Effective models can decrease the number of animals needed for efficacy trials. We develop efficient models for the testing of vaccines and drugs. Call to find out which models are currently available. CDA required.
EPM is Difficult to Diagnose and Treat
This video shows an active case, Gr. IV, of EPM
The 3 videos of this ataxic horse illustrate the similarity of EPM to CVM, or Wobbler Syndrome
What does S. neurona phenotype have to do with treating EPM?
Cross Protection with S. neurona
Protective immunity is stimulated by protozoal infections. Each phenotype of S. neurona stimulates some unique adaptive responses in the host. Our in vitro research using SAG1 phenotype challenge in horses indicates that the cellular response is phenotype specific. New evidence indicates that the horse can produce cross-protection to some, but not all, phenotypes. We found two mechanisms that elicit cross protection that we can measure. What is interesting is that while there are some similarities to the molecular sequence of the SnSAG's they are antigenically unique. Therefore, it's not unexpected that a phenotype specific response would be stimulated with infection. But it is surprising that one phenotype stimulates inter-species reactions and possibly elicits cross protection in animals. We are investigating the in vivo cross protection in horses and the relationship between the known SnSAG's. We published trials showing that SnSAG1 vaccination elicits protective immunity against homologous challenge in horses. As we understand the inter and intraspecies antigen responses we can identify an efficient strategy to elicit protection against all S. neurona infections. Understanding immunity to Sarcocystis is as important to treatment of EPM as it is to protection against sarcocystis infections.
Peptide ELISA survey results
We surveyed PEPTIDE ELISA test results and information from submission forms from November 2010 through May 2011. Equine sera submitted for testing using the Peptide ELISA that detects specific antibodies to the three antigen types of Sarcocystis neurona. These data are meaningful as more samples are analyzed. Our sample set is increasing, and sampled 0.5% of the total EPM cases anticipated in the US population annually. We are seeing trends in treatment efficacy that match the published data. The phenotype of S. neurona that infects a horse can be identified and influence treatment choices. In the example below all the sera contain common antigens that can be detected. Horse 7 is negative for active disease. The antibodies present in the remaining horses are infected. The horses with active neuroinvasive S. neurona infections are 2, 3, 4, 5 and 9. Horses 1 and 6 may resolve the infections without treatment.

SAG Antigens: What you should know about antigen types and strains
More evidence that SnSAG 1, 5, and 6 are important antigens to understand and recognize in equine infections. Find out what you should know, click here. Read the paper here.
Pathogenes Inc.
PO Box 970, Fairfield, Fl. 32634
15471 NW 112th Ave, Reddick, Fl. 32686
ph: 352-591-3221
fax: 352-591-4318
sellison